Silver Book Fact

A study of a number of osteoporosis treatments found cost-effectiveness ratios as low as $55,000 per QALY.

Mobley L, Hoerger T, Wittenborn J, Galuska D, Rao J. Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate. Medical Decision Making. 2006; 26(2): 194-206. http://mdm.sagepub.com/cgi/content/abstract/26/2/194

Reference

Title
Cost-Effectiveness of Osteoporosis Screening and Treatment with Hormone Replacement Therapy, Raloxifene, or Alendronate
Publication
Medical Decision Making
Publication Date
2006
Authors
Mobley L, Hoerger T, Wittenborn J, Galuska D, Rao J
Volume & Issue
Volume 26, Issue 2
Pages
194-206
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.  
  • Risedronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by around 5% and hip BMD by 2% to 3% in postmenopausal women with osteoporosis.  
  • Genetics can account for up to 75% of bone mineral density (BMD). Researchers have identified a gene that strongly influences peak bone mass in mice. The gene was not previously…  
  • The Study of Osteoporotic Fractures, which began over 20 years ago, found that bone mineral density (BMD) of the hip is one of the best predictors of fracture for women,…  
  • Researchers are looking at the use of micro-computed tomography and magnetic resonance imaging to better understand the relationship between bone structure and fracture risk. Other tools are being evaluated for…